← All trials
NCT01426529
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- Oct 15, 2017
- Completion date
- Oct 15, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.